DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION

Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for Active Ingredients or New Molecules A new analysis published this week in Nature Biotechnology further reveals how the

01-19-2022 Read More

CSRXP STATEMENT ON PROPOSED CMS COVERAGE DECISION FOR ADUHELM

DECISION WILL HELP PROTECT SENIORS, TAXPAYERS AND THE U.S. HEALTH SYSTEM FROM EGREGIOUS PRICING ON AN UNPROVEN TREATMENT For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected]

01-12-2022 Read More

CSRXP STATEMENT AHEAD OF COMMITTEE VOTE FOR DR. ROBERT CALIFF TO LEAD U.S. FOOD AND DRUG ADMINISTRATION

Next FDA Commissioner Must Promote Competition, Transparency And Value In The Pharmaceutical Marketplace For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington,

01-12-2022 Read More

SECOND OPINION: BIG PHARMA CEO CLAIMS “COURAGEOUS” TO PRICE UNPROVEN TREATMENT 10 TIMES ESTIMATE OF FAIR PRICE

Biogen Decision to Change Aduhelm Price After Public Outcry Demonstrates Big Pharma Prices Solely Designed to Maximize Profits During a recent interview at the J.P.

01-11-2022 Read More

BIG PHARMA WATCH: BIG PHARMA’S JANUARY PRICE HIKES CLIMB TO 588

Brand Name Drug Companies’ Business-as-Usual Approach to Price Increases Highlights Urgency for Congress to Hold the Industry Accountable In case you missed it

01-7-2022 Read More

HAPPY NEW YEAR: BIG PHARMA HIKES PRICES ON MORE THAN 400 BRAND NAME DRUGS TO RING IN 2022

Fourth Major Round Of Pandemic Price Hikes Highlight Urgency for Policymakers to Hold Big Pharma Accountable For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington,

01-3-2022 Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART I

Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch Prices Despite unprecedented attention on the crisis of prescription drug affordability

12-28-2021 Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART II

Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite unprecedented attention on the crisis of prescription drug affordability, Big Pharma maintained the industry’s

12-28-2021 Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III

Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual Despite unprecedented attention on the crisis of prescription drug affordability

12-28-2021 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.